Top

Clinical and Translational Oncology

Published in:

01-04-2019 | Brief Research Article

Optimization of oral chemotherapy in outpatient clinics in Spain: results from a survey of the Spanish Society of Medical Oncology (SEOM)

Authors: A. Santaballa, J. De Castro, J. Maurel, M. Lázaro, R. Vera, E. Alba

Published in: Clinical and Translational Oncology | Issue 4/2019

Abstract

Purpose

To determine the current management of oral and intravenous chemotherapy (OC and IVC) in outpatient clinics of Oncology Departments in Spain to detect opportunities for improvement.

Materials and methods

The Spanish Society of Medical Oncology designed a questionnaire specifically for Heads of Oncology Department: 142 were invited and 52 responded.

Results

In most centers, the waiting time (69.7%) and time at the outpatient clinic (84.8%) was shorter for patients receiving OC compared to those receiving IVC. The time spent at the outpatient clinic by the patients having OC was approximately 30 min (88.5%). In addition, the time expended by the oncologist with each patient was shorter when they were treated with OC in 21.2% of cases.

Conclusions

Patients’ waiting times and individual dedication of oncologists might be reduced by administering OC, and general management might be improved. This should be considered when planning therapies if OC is an option.

Available only for authorised users

Ramalho de Oliveira D, Brummel AR, Miller DB. Medication therapy management: 10 years of experience in a large integrated health care system. J Manag Care Pharm. 2010;16(3):185–95. https://doi.org/10.18553/jmcp.2010.16.3.185.CrossRefPubMed

Jara C, Ayala F, Virizuela JA, Oncology Day Hospital Task F. The oncology day hospital in Spain: an updated analysis of Spanish Society of Medical Oncology (SEOM) looking forward. Clin Transl Oncol. 2017;19(3):269–72. https://doi.org/10.1007/s12094-016-1610-1.CrossRefPubMedPubMedCentral

El Miguel Servet necesita un nuevo hospital de día oncológico. Cadena Ser. 2015. http://cadenaser.com/emisora/2015/10/02/radio_zaragoza/1443807602_118256.html. Accessed June 2018.

Fernandez M. Denuncian masificación en el hospital de Día oncológico de Carlos Haya. La Opinión de Málaga. 2015. http://www.laopiniondemalaga.es/malaga/2015/04/11/denuncian-masificacion-hospital-oncologico-carlos/757532.html. Accessed June 2018.

Rubiera A. El aumento de pacientes fuerza a mejorar el hospital de día oncológico de Cabueñes. La nueva España. 2016. http://www.lne.es/gijon/2016/08/19/aumento-pacientes-fuerza-mejorar-hospital/1972182.html. Accessed June 2018.

El CHN mejora la seguridad y agiliza los tratamientos oncológicos. Redacción médica. 2017. https://www.redaccionmedica.com/autonomias/navarra/el-chn-mejora-la-seguridad-y-agiliza-los-tratamientos-oncologicos-6209. Accessed June 2018.

Biganzoli L, Lichtman S, Michel JP, Papamichael D, Quoix E, Walko C, et al. Oral single-agent chemotherapy in older patients with solid tumours: a position paper from the International Society of Geriatric Oncology (SIOG). Eur J Cancer. 2015;51(17):2491–500. https://doi.org/10.1016/j.ejca.2015.08.005.CrossRefPubMed

García-Gómez R. [Abstract]. In: Garrido P, de Castro J (eds) XV congreso de la SEOM; Madrid (Spain): SEOM. 2015.

Strada MR, Palumbo R, Bernardo A, Riccardi A, Teragni C, Poggi G, et al. Intravenous or oral vinorelbine plus capecitabine as first-line treatment in HER2- metastatic breast cancer: joint analysis of 2 consecutive prospective phase II trials. Clin Breast Cancer. 2012;12(1):30–9. https://doi.org/10.1016/j.clbc.2011.11.001.CrossRefPubMed

10.

Jensen LH, Osterlind K, Rytter C. Randomized cross-over study of patient preference for oral or intravenous vinorelbine in combination with carboplatin in the treatment of advanced NSCLC. Lung Cancer. 2008;62(1):85–91. https://doi.org/10.1016/j.lungcan.2008.02.009.CrossRefPubMed

11.

European Medicines Agency. 2018. Capecitabine. Summary of Product Characteristics 2012. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002568/WC500135446.pdf. Accessed June 2018.

12.

European Medicines Agency. Summary on Vepesid and associated names for etoposide in capsules. 2017. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/referrals/Vepesid/human_referral_000419.jsp&mid=WC0b01ac05805c516f. Accessed June 2018.

13.

European Medicines Agency. List of nationally authorised medicinal products with active substance vinorelbine. 2017. http://www.ema.europa.eu/docs/en_GB/document_library/Periodic_safety_update_single_assessment/2017/12/WC500239742.pdf. Accessed June 2018.

14.

Barni S, Freier B, Garau I, Mouysset JL, Sediva M, Zamagni C, et al. Burden of advanced breast cancer for patients and caregivers in Europe: comparison of two treatment forms of vinorelbine, oral and intravenous. Curr Med Res Opin. 2016;32(11):1807–12. https://doi.org/10.1080/03007995.2016.1211518.CrossRefPubMed

15.

James RD. Improving chemotherapy capacity by switching from IV to oral vinorelbine. Eur J Oncol Pharm. 2010;4(3):14–7.

16.

Wong SF, Bounthavong M, Nguyen CP, Chen T. Outcome assessments and cost avoidance of an oral chemotherapy management clinic. J Natl Compr Canc Netw. 2016;14(3):279–85.CrossRefPubMed

17.

Chewning B, Wiederholt JB. Concordance in cancer medication management. Patient Educ Couns. 2003;50(1):75–8.CrossRefPubMed

18.

Strasser F, Sweeney C, Willey J, Benisch-Tolley S, Palmer JL, Bruera E. Impact of a half-day multidisciplinary symptom control and palliative care outpatient clinic in a comprehensive cancer center on recommendations, symptom intensity, and patient satisfaction: a retrospective descriptive study. J Pain Symptom Manage. 2004;27(6):481–91. https://doi.org/10.1016/j.jpainsymman.2003.10.011.CrossRefPubMed

19.

Fortner BV, Tauer K, Zhu L, Okon TA, Moore K, Templeton D, et al. Medical visits for chemotherapy and chemotherapy-induced neutropenia: a survey of the impact on patient time and activities. BMC Cancer. 2004;4:22. https://doi.org/10.1186/1471-2407-4-22.CrossRefPubMedPubMedCentral

20.

Le Lay K, Myon E, Hill S, Riou-Franca L, Scott D, Sidhu M, et al. Comparative cost-minimisation of oral and intravenous chemotherapy for first-line treatment of non-small cell lung cancer in the UK NHS system. Eur J Health Econ. 2007;8(2):145–51. https://doi.org/10.1007/s10198-006-0034-1.CrossRefPubMed

Title: Optimization of oral chemotherapy in outpatient clinics in Spain: results from a survey of the Spanish Society of Medical Oncology (SEOM)
Authors: A. Santaballa
J. De Castro
J. Maurel
M. Lázaro
R. Vera
E. Alba
Publication date: 01-04-2019
Publisher: Springer International Publishing
Published in: Clinical and Translational Oncology / Issue 4/2019
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI: https://doi.org/10.1007/s12094-018-1951-z

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Purpose

Materials and methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 4/2019

Recommendations by the Spanish Society of Hospital Pharmacy, the Spanish Society of Oncology Nursing and the Spanish Society of Medical Oncology for the safe management of antineoplastic medication in cancer patients

Impact of diabetes comorbidity on the efficacy and safety of FOLFOX first-line chemotherapy among patients with metastatic colorectal cancer: a pooled analysis of two phase-III studies

Goal-directed therapy in cytoreductive surgery with hyperthermic intraperitoneal chemotherapy: a prospective observational study

Quality indicators in radiation oncology: proposal of the Spanish Society of Radiation Oncology (SEOR) for a continuous improvement of the quality of care in oncology

Transarterial chemoembolization with raltitrexed-based or floxuridine-based chemotherapy for unresectable colorectal cancer liver metastasis

Effect of Paclitaxel-based Hyperthermic Intraperitoneal Chemotherapy (HIPEC) on colonic anastomosis in a rat model

Keynote webinar | Spotlight on antibody–drug conjugates in cancer